Effect of High-Intensity Focused Ultrasound on Drug Release from Doxorubicin-Loaded PEGylated Liposomes and Therapeutic Effect in Colorectal Cancer Murine Models.

The goal of the study described here was to evaluate the use of high-intensity focused ultrasound (HIFU) in drug release and its application in cancer therapy. HIFU was set to minimize hyperthermia, particularly non-specific hyperthermia, of exposed areas. An in vitro temperature-sensitive hydrogel phantom model determined the parameters of HIFU under mild condition settings (spatial average temporal average intensity [ISATA] = 83.35 W/cm(2)). PEGylated liposomal indocyanine green (LCLP-ICG) and PEGylated liposomal doxorubicin (LCLP-Dox) were prepared with the same mole ratio to allow direct comparison of drug release in vitro and in vivo. We induced drug release with HIFU treatment using LCLP-ICG coupled with optical imaging in vitro and in vivo. The size distribution changes in LCLP-ICG in vitro and fluorescence intensity changes in ICG after intra-tumoral injection of LCLP-ICG into CT26 solid tumors in vivo followed by HIFU confirmed the feasibility of the system. We validated the therapeutic effect of HIFU treatment of the CT26 mouse tumor model. The tumor growth rate was significantly reduced (p < 0.05) only in the group administered LCLP-Dox followed by cycles of HIFU treatment, and the chemotherapy of the CT26 solid tumors was found to be highly efficient.